Records containing: Schizoaffective Disorder
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2011-11-01Epidemiological Observational Non-interventional Study to Research the Prevalence of Bipolar Criteria of Hospital In-patients With Schizophrenia and Patients With Recurrent Depression
-
CLINICAL_TRIALS study record update · 2011-10-06Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial
-
CLINICAL_TRIALS study record update · 2011-09-07Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia. (BMS)
-
CLINICAL_TRIALS study record update · 2011-09-07Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia, (SFBRI).
-
CLINICAL_TRIALS study record update · 2011-08-03Metabolic Side Effects, Diet and Exercise Counseling and Brain Function in a Naturalistic Clinical Trial of Clozapine for Treatment Resistant Bipolar and Schizoaffective Disorder
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2011-07-29The Effects of Ziprasidone 320 mg on Glucose and Plasma Lipids in Patients With Diabetes Type II and Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-07-25Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain
-
CLINICAL_TRIALS study record update · 2011-07-21A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome
-
CLINICAL_TRIALS study record update · 2011-07-13A Multicenter, Open Label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (Seroquel) and Risperidone (Risperdal) in the Long Term Treatment of Participants With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-06-08A Placebo- and Positive-controlled, Randomized Study Evaluating QT and QTc Intervals Following Administration of Immediate-release Paliperidone in Subjects With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-06-08Comparison of Steady-state Pharmacokinetics of Paliperidone After Extended-release OROS� Paliperidone 15 mg and Immediate-release Oral Risperidone 8 mg b.i.d. in Subjects With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-06-08Open-label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-dose Extended-release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
-
CLINICAL_TRIALS study record update · 2011-05-19Aggressiveness and Agitation of Acute Psychotic Patients: Influence in Safety and Effectiveness of Risperidone Treatment
-
CLINICAL_TRIALS study record update · 2011-05-19Study PROFILe3: Clinic Observations Profile of Relapse and Readmission in Emergency/Acute Settings: Epidemiologic Survey in Schizophrenic Patients
-
CLINICAL_TRIALS study record update · 2011-05-19BMI-2002 Study: Evaluation of Functionality and Evolution of Body Weight of Psychotic Patients With a High Body Mass Index
-
CLINICAL_TRIALS study record update · 2011-05-18A 52-wk Prospective, Randomized, Double-blind, Multicenter Study of Relapse Following Transition From Oral Antipsychotic Medication to 2 Different Doses (25 or 50 mg Every 2 Wks) of Risperidone Long-acting Microspheres (Risperdal� CONSTA�) in Adults With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-05-18A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating QT/QTc Intervals Following Administration of Extended-release Paliperidone and Quetiapine in Subjects With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-05-17Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open Label Follow up Trial of RIS-INT-57 and RIS-INT-61.
-
CLINICAL_TRIALS study record update · 2011-05-17Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open-label Follow-up Trial of RIS-INT-62 and RIS-INT-85.
-
CLINICAL_TRIALS study record update · 2011-05-17Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?
-
CLINICAL_TRIALS study record update · 2011-05-02Double Blind Placebo Controlled Investigation of Amantadine for Retarding Weight Gain in First Episode Adlt Psychotic Subjects Beginning Therapy With Olanzapine.
-
CLINICAL_TRIALS study record update · 2011-03-28Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2011-03-23A Randomized Trial Administering Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-01-20A Randomized Trial Administering Raloxifene vs Placebo as add-on to Antipsychotics in Post Menopausal Patients With Schizophrenia or Schizoaffective Disorder
-
CLINICAL_TRIALS study record update · 2011-01-04A Multicentre, Placebo-controlled Trial of Eicosapentaenoic Acid (EPA) and Antioxidant Supplementation in the Treatment of Schizophrenia and Related Disorders